Franco Goytia, a 2017 YLAI Fellow and the co-founder of CASPR Biotech, an Argentine startup, has developed a Covid-19 test using CRISPR gene editing technology. The U.S. patented kit detects antibodies in less than an hour at approximately half the cost of a polymerase chain reactor - the current standard for Covid-19 diagnosis. A similar test developed by Massachusetts Institute of Technology (MIT) received U.S. Food and Drug Administration (FDA) approval in early May. Both Grid Exponential (a Latin American biotech company) and IndieBio (the largest biotech investor in the world) have signed on as investors in Franco’s CRISPR technology. Way to go Franco!